Search

Displaying results 421 - 430 of 4650 in total
  1. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. … The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.

    Products: ALDURAZYME 100 U/ML IV INFUZYON ICIN KONSANTRE COZELTI, 1 ADET
  2. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … [A241045] In December 2022, ublituximab was approved by the US FDA for the treatment of relapsing forms of multiple sclerosis, becoming the first and only anti-CD20 monoclonal antibody for multiple sclerosis

  3. Drug

    Calcium acetate

    go.drugbank.com/drugs/DB00258
    Approved

    The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.

  4. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. … In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections.

  5. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically … [A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021.

  6. Drug

    Valganciclovir

    go.drugbank.com/drugs/DB01610
    ApprovedInvestigational

    After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. … Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.

  7. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation.[L50336]

  8. Drug

    Flortaucipir F-18

    go.drugbank.com/drugs/DB14914
    ApprovedInvestigational

    It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114]

  9. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.

  10. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.